Sen. John Fetterman, D-Pa., has signed on to the reintroduced Cannabis Administration and Opportunity Act, joining 17 Democratic co-sponsors on legislation that would remove marijuana from the federal Controlled Substances Act entirely - not simply reschedule it. That distinction matters more than it might seem. Rescheduling to Schedule III, the path favored by some in the current administration, would ease certain tax burdens but leave the underlying federal prohibition intact. De-scheduling, by contrast, would let states set their own rules while shifting oversight to the Alcohol and Tobacco Tax and Trade Bureau, a body that already regulates two other vice industries with mature compliance frameworks.
For operators, the practical stakes sit in the plumbing of the business. A newly created Center for Cannabis Products would take over labeling, distribution and sales rules, while the bill's 280E fix would finally let cannabis companies deduct ordinary business expenses the way any other retailer does. That single change could reshape margins for multi-state operators currently taxed on gross revenue rather than net profit. It would also open the door, at least in theory, to interstate commerce and normalized banking relationships - a shift that would ripple through everything from wholesale pricing to point-of-sale infrastructure. Dispensaries in mature markets already lean on specialized retail technology; in Maine, for instance, operators use POS software for Maine cannabis retailers to manage compliance logs, inventory tracking and tax reporting under state rules that would need to adapt if federal law changes underneath them. POS software for Maine cannabis retailers
What the Bill Actually Changes on the Ground
Beyond taxation, the legislation touches consumer safety and workplace policy in ways operators should watch closely. It directs the Department of Transportation to develop cannabis-impaired driving standards and pushes states toward open-container laws modeled on alcohol regulation - an acknowledgment that de-scheduling without impairment science in place creates real public-safety gaps. It also eliminates pre-employment and random drug testing for federal employees, a provision that could pressure private employers to revisit their own testing policies. None of this legalizes impaired driving or workplace intoxication; it simply reframes cannabis under a regulatory structure closer to alcohol than to Schedule I narcotics.
A Divided Delegation and a Familiar Political Fault Line
Fetterman's support puts him at odds with Pennsylvania's junior senator, Republican Dave McCormick, who joined 21 GOP colleagues in a December letter opposing even the more modest rescheduling move. McCormick has called himself a supporter of medical marijuana, which underscores a pattern seen across the country: lawmakers who accept regulated medical programs often balk at broader adult-use frameworks or full de-scheduling. A Susquehanna Polling and Research survey from April found majority support for recreational legalization across party lines in Pennsylvania - 72% among Democrats, 67% among Republicans, 64% among independents - a gap between public opinion and legislative caution that shows up in state after state.
Why Passage Remains Uncertain
Similar versions of this bill have circulated in the previous two Congressional sessions without reaching a floor vote, and nothing about the current partisan math suggests this attempt clears that bar easily. Twenty-four states now allow recreational marijuana and 35 permit medical use, yet federal law still classifies unlicensed cannabis as Schedule I. That mismatch continues to complicate banking, interstate shipping, lab testing standardization and tax treatment for every operator working across state lines. Whether this bill moves forward or stalls again, the underlying tension - state markets outpacing federal law - isn't going away.